Cargando…

Circulating Cytokines in Metastatic Breast Cancer Patients Select Different Prognostic Groups and Patients Who Might Benefit from Treatment beyond Progression

Cancer induces immune suppression to overcome its recognition and eradication by the immune system. Cytokines are messengers able to modulate immune response or suppression. There is great interest in the evaluation of their changes during treatment in order to identify their relationship with clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Paccagnella, Matteo, Abbona, Andrea, Michelotti, Andrea, Geuna, Elena, Ruatta, Fiorella, Landucci, Elisabetta, Denaro, Nerina, Vanella, Paola, Lo Nigro, Cristiana, Galizia, Danilo, Merlano, Marco, Garrone, Ornella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781714/
https://www.ncbi.nlm.nih.gov/pubmed/35062739
http://dx.doi.org/10.3390/vaccines10010078
_version_ 1784638144990150656
author Paccagnella, Matteo
Abbona, Andrea
Michelotti, Andrea
Geuna, Elena
Ruatta, Fiorella
Landucci, Elisabetta
Denaro, Nerina
Vanella, Paola
Lo Nigro, Cristiana
Galizia, Danilo
Merlano, Marco
Garrone, Ornella
author_facet Paccagnella, Matteo
Abbona, Andrea
Michelotti, Andrea
Geuna, Elena
Ruatta, Fiorella
Landucci, Elisabetta
Denaro, Nerina
Vanella, Paola
Lo Nigro, Cristiana
Galizia, Danilo
Merlano, Marco
Garrone, Ornella
author_sort Paccagnella, Matteo
collection PubMed
description Cancer induces immune suppression to overcome its recognition and eradication by the immune system. Cytokines are messengers able to modulate immune response or suppression. There is great interest in the evaluation of their changes during treatment in order to identify their relationship with clinical outcome. We evaluated 18 cytokines in breast cancer patients treated with eribulin before starting treatment (T0) and after four courses of therapy (T1). Longitudinal modifications were considered and cytokine clusters through PCA and HCPC correlated to patients’ outcomes were identified. Forty-one metastatic breast cancer patients and fifteen healthy volunteers were included. After clustering, we identified at T0 six patient clusters with different risk of relapse and death. At T1, only four clusters were identified, and three of them accounted for thirty-eight of forty-one patients, suggesting a possible role of treatment in reducing heterogeneity. The cluster with the best survival at T1 was characterized by low levels of IL-4, IL-6, IL-8, IL-10, CCL-2, CCL-4, and TGF-β. The cluster showing the worst survival encompassed high levels of IL-4, IL-6, IL-8, IL-10, CCL-2, and IFN-γ. A subgroup of patients with short progression-free survival (PFS) and long overall survival (OS) was comprised in the cluster characterized by low levels of CCL-2, IL-6, IL-8, IL-10, and IL-12 at T0. Our data support the prognostic significance of longitudinal serum cytokine analysis. This approach may help identify patients for whom early treatment stop avoids needless toxicity or might justify treatment beyond early progression. Further investigations are required to validate this hypothesis.
format Online
Article
Text
id pubmed-8781714
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87817142022-01-22 Circulating Cytokines in Metastatic Breast Cancer Patients Select Different Prognostic Groups and Patients Who Might Benefit from Treatment beyond Progression Paccagnella, Matteo Abbona, Andrea Michelotti, Andrea Geuna, Elena Ruatta, Fiorella Landucci, Elisabetta Denaro, Nerina Vanella, Paola Lo Nigro, Cristiana Galizia, Danilo Merlano, Marco Garrone, Ornella Vaccines (Basel) Article Cancer induces immune suppression to overcome its recognition and eradication by the immune system. Cytokines are messengers able to modulate immune response or suppression. There is great interest in the evaluation of their changes during treatment in order to identify their relationship with clinical outcome. We evaluated 18 cytokines in breast cancer patients treated with eribulin before starting treatment (T0) and after four courses of therapy (T1). Longitudinal modifications were considered and cytokine clusters through PCA and HCPC correlated to patients’ outcomes were identified. Forty-one metastatic breast cancer patients and fifteen healthy volunteers were included. After clustering, we identified at T0 six patient clusters with different risk of relapse and death. At T1, only four clusters were identified, and three of them accounted for thirty-eight of forty-one patients, suggesting a possible role of treatment in reducing heterogeneity. The cluster with the best survival at T1 was characterized by low levels of IL-4, IL-6, IL-8, IL-10, CCL-2, CCL-4, and TGF-β. The cluster showing the worst survival encompassed high levels of IL-4, IL-6, IL-8, IL-10, CCL-2, and IFN-γ. A subgroup of patients with short progression-free survival (PFS) and long overall survival (OS) was comprised in the cluster characterized by low levels of CCL-2, IL-6, IL-8, IL-10, and IL-12 at T0. Our data support the prognostic significance of longitudinal serum cytokine analysis. This approach may help identify patients for whom early treatment stop avoids needless toxicity or might justify treatment beyond early progression. Further investigations are required to validate this hypothesis. MDPI 2022-01-05 /pmc/articles/PMC8781714/ /pubmed/35062739 http://dx.doi.org/10.3390/vaccines10010078 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Paccagnella, Matteo
Abbona, Andrea
Michelotti, Andrea
Geuna, Elena
Ruatta, Fiorella
Landucci, Elisabetta
Denaro, Nerina
Vanella, Paola
Lo Nigro, Cristiana
Galizia, Danilo
Merlano, Marco
Garrone, Ornella
Circulating Cytokines in Metastatic Breast Cancer Patients Select Different Prognostic Groups and Patients Who Might Benefit from Treatment beyond Progression
title Circulating Cytokines in Metastatic Breast Cancer Patients Select Different Prognostic Groups and Patients Who Might Benefit from Treatment beyond Progression
title_full Circulating Cytokines in Metastatic Breast Cancer Patients Select Different Prognostic Groups and Patients Who Might Benefit from Treatment beyond Progression
title_fullStr Circulating Cytokines in Metastatic Breast Cancer Patients Select Different Prognostic Groups and Patients Who Might Benefit from Treatment beyond Progression
title_full_unstemmed Circulating Cytokines in Metastatic Breast Cancer Patients Select Different Prognostic Groups and Patients Who Might Benefit from Treatment beyond Progression
title_short Circulating Cytokines in Metastatic Breast Cancer Patients Select Different Prognostic Groups and Patients Who Might Benefit from Treatment beyond Progression
title_sort circulating cytokines in metastatic breast cancer patients select different prognostic groups and patients who might benefit from treatment beyond progression
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781714/
https://www.ncbi.nlm.nih.gov/pubmed/35062739
http://dx.doi.org/10.3390/vaccines10010078
work_keys_str_mv AT paccagnellamatteo circulatingcytokinesinmetastaticbreastcancerpatientsselectdifferentprognosticgroupsandpatientswhomightbenefitfromtreatmentbeyondprogression
AT abbonaandrea circulatingcytokinesinmetastaticbreastcancerpatientsselectdifferentprognosticgroupsandpatientswhomightbenefitfromtreatmentbeyondprogression
AT michelottiandrea circulatingcytokinesinmetastaticbreastcancerpatientsselectdifferentprognosticgroupsandpatientswhomightbenefitfromtreatmentbeyondprogression
AT geunaelena circulatingcytokinesinmetastaticbreastcancerpatientsselectdifferentprognosticgroupsandpatientswhomightbenefitfromtreatmentbeyondprogression
AT ruattafiorella circulatingcytokinesinmetastaticbreastcancerpatientsselectdifferentprognosticgroupsandpatientswhomightbenefitfromtreatmentbeyondprogression
AT landuccielisabetta circulatingcytokinesinmetastaticbreastcancerpatientsselectdifferentprognosticgroupsandpatientswhomightbenefitfromtreatmentbeyondprogression
AT denaronerina circulatingcytokinesinmetastaticbreastcancerpatientsselectdifferentprognosticgroupsandpatientswhomightbenefitfromtreatmentbeyondprogression
AT vanellapaola circulatingcytokinesinmetastaticbreastcancerpatientsselectdifferentprognosticgroupsandpatientswhomightbenefitfromtreatmentbeyondprogression
AT lonigrocristiana circulatingcytokinesinmetastaticbreastcancerpatientsselectdifferentprognosticgroupsandpatientswhomightbenefitfromtreatmentbeyondprogression
AT galiziadanilo circulatingcytokinesinmetastaticbreastcancerpatientsselectdifferentprognosticgroupsandpatientswhomightbenefitfromtreatmentbeyondprogression
AT merlanomarco circulatingcytokinesinmetastaticbreastcancerpatientsselectdifferentprognosticgroupsandpatientswhomightbenefitfromtreatmentbeyondprogression
AT garroneornella circulatingcytokinesinmetastaticbreastcancerpatientsselectdifferentprognosticgroupsandpatientswhomightbenefitfromtreatmentbeyondprogression